Group 1 - The core viewpoint is that pharmaceutical funds have significantly outperformed the market, with an average net value growth rate of over 19% as of June 18, making them a focal point for investors [1][2] - Among all public funds, pharmaceutical funds accounted for 49 out of the top 100 funds in terms of performance, indicating strong interest and investment potential in this sector [2] - The average net value growth rate for pharmaceutical funds reached 19.66%, with several funds achieving around 70% growth, particularly those focused on innovative drugs [2] Group 2 - Key driving factors for the pharmaceutical sector's performance include supportive policies such as improved drug procurement mechanisms and accelerated new drug approval processes [3] - The period from 2025 to 2028 is projected to be critical for Chinese innovative drug companies, with 2025 expected to be a pivotal year for profitability [3] - The innovative drug sector is anticipated to enter a sustained growth cycle, driven by clinical catalysts and significant financial performance improvements [3] Group 3 - Fund managers express optimism about the innovative drug sector, highlighting its growth potential and the favorable policy environment that provides substantial development space for pharmaceutical companies [4] - The innovative drug sector is seen as undervalued, with many companies now presenting attractive valuations, leading to increased investment interest [4] - Recent performance in the innovative drug sector is attributed to the market's recognition of the value of high-quality Chinese innovative drug assets [4] Group 4 - Collaborations between domestic innovative drug companies and multinational pharmaceutical firms are enhancing the global competitiveness of Chinese innovative drugs, prompting a reassessment of their pipeline values [5]